General risks As a blister agent, cantharidin has the potential to cause adverse effects when used medically; for this reason, it has been included in a list of "problem drugs" used by dermatologists and emergency personnel. However, this references unregulated sources of cantharidin. In July 2023, the US FDA approved a topical formulation of cantharidin (Ycanth) for the treatment of molluscum contagiosum.
General risks As a blister agent cantharidin has the potential to cause adverse effects when used medically; for this reason it has been included in a list of "problem drugs" used by dermatologists and emergency personnel However this references unregulated sources of cantharidin In July 2023 the US FDA approved a topical formulation of cantharidin (Ycanth) for the treatment of molluscum contagiosum